Home/Biosimilar Atlas/Bevacizumab/CuraTeQ bevacizumab

CuraTeQ bevacizumab

Bevacizumab biosimilar developed by CuraTeQ Biologics (Aurobindo). Reference product Avastin.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: CuraTeQ Biologics · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOMay 2026permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
BevacizumabmoleculeCuraTeQ Biologicsdeveloper1 of 7markets0trials behind it3other products, same developer7rival developers in its markets

About CuraTeQ bevacizumab

CuraTeQ, the biologics arm of Aurobindo, received its bevacizumab permission in India in May 2026, the most recent Indian entrant and the seventh domestic maker of the molecule.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
CuraTeQ Biologics Private Limited
Pathway
Similar Biologic, manufacture and marketing permission
Approved
May 2026
Application or permission
MF/BIO/26/000060
Indications as licensed
Metastatic colorectal cancer and other reference indications
Presentations
100 mg/4 mL and 400 mg/16 mL
Source
S011 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where CuraTeQ bevacizumab holds an approval, these are the other bevacizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO7Biocon Biologics (Jobevne / Abevmy / Krabeva), Dr. Reddy's Laboratories (Dr. Reddy's bevacizumab), Enzene Biosciences (Enzene Biosciences bevacizumab), Hetero (Hetero bevacizumab), Intas Pharmaceuticals (Intas bevacizumab), Reliance Life Sciences (Reliance Life Sciences bevacizumab), Zydus Lifesciences (Zydus bevacizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by CuraTeQ Biologics: Dazublys / CuraTeQ trastuzumab, Dyrupeg / Cavoley, Zefylti.

Chronology

Sources

All bevacizumab biosimilars

Planning bevacizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.